Trexquant Investment LP Reduces Stock Holdings in Stoke Therapeutics, Inc. $STOK

Key Points

• Trexquant Investment LP has reduced its holdings in Stoke Therapeutics by 16.4%, now owning around 86,140 shares valued at approximately $573,000.
• During the first quarter, several hedge funds made significant changes, with GAMMA Investing LLC increasing its position by 1,842%, now holding 5,360 shares valued at $36,000.
• Stoke Therapeutics recently reported earnings of ($0.40) per share for the quarter, surpassing analyst estimates of ($0.57), with revenues falling short at $13.82 million against a consensus of $31.51 million.

Trexquant Investment LP lessened its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 16.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 86,140 shares of the company's stock after selling 16,891 shares during the quarter. Trexquant Investment LP owned approximately 0.16% of Stoke Therapeutics worth $573,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of STOK. GAMMA Investing LLC increased its stake in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares during the last quarter. AlphaQuest LLC bought a new position in Stoke Therapeutics during the 1st quarter valued at about $72,000. US Bancorp DE lifted its holdings in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after purchasing an additional 11,108 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Stoke Therapeutics in the 1st quarter valued at about $92,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth approximately $107,000.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 14,922 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total transaction of $300,529.08. Following the sale, the general counsel directly owned 18,176 shares of the company's stock, valued at $366,064.64. This represents a 45.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider directly owned 18,469 shares in the company, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 107,719 shares of company stock valued at $2,063,359. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded down $0.42 during mid-day trading on Friday, hitting $23.46. The company had a trading volume of 1,030,859 shares, compared to its average volume of 957,451. The firm has a fifty day moving average price of $16.05 and a 200 day moving average price of $11.54. The company has a market capitalization of $1.29 billion, a PE ratio of 27.60 and a beta of 1.14. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $24.60.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on STOK. Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the company a "buy" rating in a report on Monday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.